is an academic and clinical instructor, Kaiser Permanente School of Anesthesia. E-mail:
is a staff CRNA, Department of Anesthesiology, University of California, Davis. E-mail:
AANA J. 2022 Jun;90(3):225-233.
Buprenorphine has been widely used in opioid medication assisted treatment (MAT) in the past decade. However, due to misinterpretation of its intrinsic mu opioid receptor activity extrapolated from preclinical and animal data, buprenorphine's clinical application in pain management has been greatly limited. Buprenorphine acts as a full mu agonist with fewer side effects compared to traditional opioids and can be effectively used in the treatment of acute and chronic pain. A strong body of evidence demonstrates that buprenorphine is an effective analgesic agent in both adult and pediatric surgical patients. In addition, buprenorphine has been successfully used in treating chronic pain, particularly in cancer pain and neuropathic pain. In this Journal course, buprenorphine's receptor pharmacology and pharmacokinetics are reviewed. Specifically, misinterpretation of its intrinsic mu receptor activity, and both analgesic ceiling effect and efficacy are clarified. Differences between suboxone and buprenorphine, and specific applications are explained. Pain management options and guidelines for surgical patients on buprenorphine are discussed, as well.
在过去十年中,丁丙诺啡已广泛用于阿片类药物药物辅助治疗(MAT)。然而,由于对其从临床前和动物数据推断出的内在μ阿片受体活性的误解,丁丙诺啡在疼痛管理中的临床应用受到了极大限制。与传统阿片类药物相比,丁丙诺啡作为一种完全的μ激动剂,副作用较少,可有效用于治疗急性和慢性疼痛。大量证据表明,丁丙诺啡是成人和儿科手术患者有效的镇痛剂。此外,丁丙诺啡已成功用于治疗慢性疼痛,特别是癌症疼痛和神经性疼痛。在本期刊课程中,回顾了丁丙诺啡的受体药理学和药代动力学。具体来说,澄清了对其内在μ受体活性以及镇痛封顶效应和疗效的误解。解释了苏诺酮和丁丙诺啡之间的差异以及特定应用。还讨论了手术患者使用丁丙诺啡的疼痛管理选择和指南。